The Summary
This Bayesian longitudinal meta-analysis analyzed data from six studies involving 1,776 participants to model weight regain after stopping semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound). Researchers found that after losing an average of 15.35 kg, participants regained about 1.04 kg per month once treatment ended. The model projected that patients regain 50% of their lost weight within 7.5 months and return to their baseline weight by 15 months. While behavioral support showed a weak trend toward slowing regain, no significant difference was found between the two medications.
Why this is interesting
While many knew that stopping GLP-1 medications could lead to weight regain, this study quantifies the precise speed of the bounce-back. Many patients hope lifestyle changes alone can sustain their weight loss post-treatment. However, these findings suggest that obesity is a chronic condition requiring long-term management. For readers, it highlights that stopping these blockbuster drugs without a proactive, medically supervised maintenance plan will likely reverse their hard-earned progress within a year. It underscores the reality that these treatments are generally lifelong commitments rather than quick fixes.